[ 1 ] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009[J]. CA Cancer J Clin, 2009, 59(4): 225-249.
[2]
[ 2 ] Jema1 A, Bray F, Center MM, et a1. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[3]
[ 9 ] Yao Y, Guo G, Ni Z, et al. Cloning and characterization of microRNAs from wheat (Triticum aestivum L.)[J]. Genome Biol, 2007, 8(6): R96.
[4]
Raymond CK, Roberts BS, Garrett-Engele P, et al. Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs[J]. RNA, 2005, 11(11): 1737-1744.
[5]
Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation[J]. Circ Res, 2007, 100(11): 1579-1588.
[6]
Zhu S, Si ML, Wu H, et al. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1)[J]. J Biol Chem, 2007, 282(19): 14328-14336.
[7]
Graser A, Stieber P, Nagel D, et al. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population[J]. Gut, 2009, 58(2): 241-248.
[8]
Bandrés E, Cubedo E, Agirre X, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues[J]. Mol Cancer, 2006, 5(1): 29-38.
[9]
Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps[J]. Gut, 2012, 61(5): 739-745.
[10]
Link A, Balaguer F, Shen Y, et al. Fecal mieroRNAs as novel biomarkers for colon cancer screening[J]. Cancer Epidemiol Biomarkers Prey, 2010, 19(7): 1766-1774.
[11]
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J]. Br J Haematol, 2008, 141(5): 672-675.
[12]
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006.
[13]
Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer[J]. Oncology, 2007, 72(5/6): 397-402.
[14]
Yamamichi N, Shimomura R, Inada K, et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development[J]. Clin Cancer Res, 2009, 15(12): 4009-4016.
Liu K, Li G, Fan C, et al. Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer[J]. J Int Med Res, 2011, 39(6): 2288-2295.
[18]
[ 8 ] Castoldi M, Schmidt S, Benes V, et al. miChip: an array-based method for microRNA expression profiling using locked nucleic acid capture probes[J]. Nat Protoc, 2008, 3(2): 321-329.
[19]
Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer[J]. Oncogene, 2008, 27(15): 2128-2136.
[20]
Chen Y, Liu W, Chao T, et al. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G[J]. Cancer Lett, 2008, 272(2): 197-205.
Fujita S, Ito T, Mizutani T, et al. miR-21 gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism[J]. J Mol Biol, 2008, 378(3): 492-504.
[23]
Qin W, Zhao B, Shi Y, et al. BMPRⅡ is a direct target of miR-21[J]. Acta Biochim Biophys Sin (Shanghai), 2009, 41(7): 618-623.
[24]
Lieberman D. Progress and challenges in colorectal cancer screening and surveitlance[J]. Gastroenterology, 2010, 138(6): 2115-2126.
[25]
Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci USA, 2006, 103(7): 2257-2261.
[26]
Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro[J]. Pharmacol Res, 2007, 56(3): 248-253.
[27]
Yantiss RK, Goodarzi M, Zhou XK, et al. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma[J]. Am J Surg Pathol, 2009, 33(4): 572-582.
[28]
Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening[J]. Gut, 2009, 58(10): 1375-1381.
[29]
Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases[J]. Cancer Genet Cytogenet, 2010, 200(2): 154-160.
[30]
Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer[J]. Ann Surg, 2012, 256(3): 544-551.
[31]
Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J]. JAMA, 2008, 299(4): 425-436.
[32]
Shibuya H, Iinuma H, Shimada R, et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer[J]. Oncology, 2010, 79(3/4): 313-320.
[33]
[ 3 ] Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854.
[34]
[ 4 ] Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase Ⅱ[J]. EMBO J, 2004, 23(20): 4051-4060.
